ANGO

AngioDynamics Inc

Add to Watchlist

Advanced Chart

8.990

+0.3(3.452%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

9.100

Open

8.690

VWAP

8.90

Vol

879.79K

Mkt Cap

365.06M

Low

8.635

Amount

7.83M

EV/EBITDA(TTM)

170.88

Total Shares

40.05M

296.98M

EV/OCF(TTM)

P/S(TTM)

1.21

AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. Its product categories include oncology, venous therapies, vascular interventions, and ports. Its oncology products include Model 1500X RF Generator, IsoLoc Endorectal Balloon, Habib 4X Laparoscopic Bipolar Resection Device, Habib 4X Bipolar Resection Device, and Alatus. Its venous therapies include VenaCure EVLT 1470 Pro Laser, VenaCure EVLT System, VenaCure EVLT Procedure Packs, and others.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q3

FY2026Q2

FY2026Q1

75.95M

+5.48%

-0.085

-383.33%

76.13M

+4.51%

-0.090

+125%

72.69M

+7.71%

-0.117

+6.82%

Estimates Revision

The market is revising Upward the revenue expectations for AngioDynamics, Inc. (ANGO) for FY2026, with the revenue forecasts being adjusted by 0.32% over the past three months. During the same period, the stock price has changed by -2.81%.

Revenue Estimates for FY2026

Revise Upward

+0.32%

In Past 3 Month

EPS Estimates for FY2026

Revise Upward

+8.77%

In Past 3 Month

Stock Price

Go Down

-2.81%

In Past 3 Month

2 Analyst Rating

72.41% Upside

Wall Street analysts forecast ANGO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANGO is 15.50 USD with a low forecast of 15.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

72.41% Upside

Current: 8.990

Low

15.00

Averages

15.50

High

16.00

72.41% Upside

Current: 8.990

Low

15.00

Averages

15.50

High

16.00

Canaccord

John Young

Buy

maintain

$15 -> $17

2025-07-16

New

Reason

Canaccord

John Young

Price Target

$15 -> $17

2025-07-16

New

maintain

Buy

Reason

Canaccord analyst John Young raised the firm's price target on AngioDynamics to $17 from $15 and keeps a Buy rating on the shares. The firm said the company had another well-executed quarter, driven by growth in its Med-Tech business with nice beats across the board. Med-Tech, Med-Device, total revenues, adj. EBITDA and adj. EPS all beat estimates, capping off a momentum-building year for the company and there wasn't much thesis changing news for the company during the quarter.

Lake Street

Buy

initiated

$24

2025-07-16

New

Reason

Lake Street

Price Target

$24

2025-07-16

New

initiated

Buy

Reason

Lake Street initiated coverage of AngioDynamics with a Buy rating and $24 price target. The firm says the company has transformed its portfolio into faster-growth and higher-margin cardiovascular and cancer treatment products. The Street is missing AngioDynamics' strategic realignment as the shares should be valued more in line with higher multiple medical technology companies, the analyst tells investors in a research note.

HC Wainwright & Co.

Yi Chen

Strong Buy

Maintains

$15 → $16

2025-04-07

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$15 → $16

2025-04-07

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Yi Chen

Strong Buy

Maintains

$14 → $15

2025-01-10

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$14 → $15

2025-01-10

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Yi Chen

Strong Buy

Reiterates

$14

2024-12-10

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$14

2024-12-10

Reiterates

Strong Buy

Reason

Canaccord Genuity

William Plovanic

Strong Buy

Maintains

$13 → $12

2024-10-04

Reason

Canaccord Genuity

William Plovanic

Price Target

$13 → $12

2024-10-04

Maintains

Strong Buy

Reason

Canaccord lowered the firm's price target on AngioDynamics to $12 from $13 and keeps a Buy rating on the shares. The firm said they believe they delivered another solid quarter with $67.5M in Q1/25 revenue, but think the stock reaction is driven by missing the consensus revenue estimate and the seasonally high Q1 cash burn.

See All Ratings

Valuation Metrics

The current forward P/E ratio for AngioDynamics Inc (ANGO.O) is -28.03, compared to its 5-year average forward P/E of -75.71. For a more detailed relative valuation and DCF analysis to assess AngioDynamics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-75.71

Current PE

-28.03

Overvalued PE

316.90

Undervalued PE

-468.31

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-9.51

Current EV/EBITDA

55.51

Overvalued EV/EBITDA

174.69

Undervalued EV/EBITDA

-193.71

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

1.78

Current PS

1.15

Overvalued PS

2.64

Undervalued PS

0.92